New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
18:54 EDTADBE, NIHD, NUVA, UTX, PAY, SZYM, CYTX, ZQKOn The Fly: After Hours Movers
UP AFTER EARNINGS: Adobe (ADBE), up 6%... ALSO HIGHER: Solazyme (SZYM), up 10% after filing a $30M mixed securities shelf... NuVasive (NUVA), up 3% after releasing $62.5M from escrow following court ruling... DOWN AFTER EARNINGS: Quicksilver (ZQK), down 16%... VeriFone Systems (PAY), down 6%... ALSO LOWER: NII Holdings (NIHD), down 6% after naming an interim CEO... Cytori Therapeutics (CYTX), down 12% after proposing a common stock offering... United Technologies (UTX), down 1% after providing FY12, FY13 EPS guidance.
News For ADBE;SZYM;NUVA;ZQK;PAY;NIHD;CYTX;UTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
07:17 EDTUTXAirbus A320neo's engine issues should be fixed by April, Reuters says
Subscribe for More Information
February 11, 2016
16:10 EDTNUVANuVasive sees Ellipse acquisition accretive to 2016 EPS by 1c
Sees acquisition accelerating NuVasive revenue growth to high single-digits in 2016.
16:09 EDTNUVANuVasive to selectively explore M&A opportunities
"Very selectively, we also intend to explore compelling inorganic opportunities that add value, such as today's completion of the acquisition of Ellipse Technologies, and reinforce our focus on transformative spine solutions," the company said.
16:08 EDTNUVANuVasive sees FY16 adjusted EPS $1.48, consensus $1.49
Sees FY16 revenue $923M, consensus $881.1M.
16:07 EDTNUVANuVasive reports Q4 adjusted EPS 35c, consensus 31c
Reports Q4 revenue $215.3M, consensus $215.27M.
February 10, 2016
07:07 EDTCYTXCytori to present two year Scleroderma data at Systemic Sclerosis World Congress
Subscribe for More Information
05:06 EDTADBEAdobe implied volatility of 50 at upper end of index mean range
Subscribe for More Information
February 9, 2016
14:18 EDTUTXBoeing selects UTC Aerospace to provide landing gear for U.S. Air Force
UTC Aerospace Systems has been selected by The Boeing Company (BA) to continue to provide landing gear in support of the United States Air Force fleet of the Boeing C-17 Globemaster III aircraft, as well as continued new production support of the AH-64E Apache helicopter. The C-17 spares program encompasses two years of demand, and support for the AH-64E includes all awarded contracts through 2018. UTC Aerospace Systems is a unit of United Technologies (UTX).
08:47 EDTUTXNORESCO wins $28M energy savings performance contract with Georgia
NORESCO has won a $28M guaranteed energy savings performance contract with the Georgia Department of Corrections for work at five sites across the state. NORESCO is a unit of United Technologies. The project includes reconfiguration of three central boiler plants along with domestic hot water improvements, significant water conservation gains through equipment retrofits and controls and improved reliability and performance through heating, ventilating and air conditioning upgrades.
February 8, 2016
07:01 EDTCYTXCytori Therapeutics reports interim data on U.S. Phase II osteoarthritis trial
Cytori Therapeutics announced the top-line data as part of the pre-specified partial unblinding of 24 week follow up data from the company's ACT-OA trial. The trial is a U.S. phase II randomized, double-blind, placebo controlled trial designed to evaluate the safety and feasibility at 48 weeks of a single intra-articular knee injection of the ECCO-50 cellular therapeutic in patients with chronic knee pain due to osteoarthritis. "Key endpoints and trends observed thus far suggest that a beneficial effect may be attributable to a single intra-articular administration of ECCO-50 in patients with osteoarthritis of the knee," said Dr. Marc H. Hedrick, President and CEO. "The full 48 week data set is the next important milestone in this program. While we continue to move our clinical pipeline along, the company will remain intensely focused on bringing to market our lead therapeutic for scleroderma which is currently in phase III." The primary goal of the ACT-OA trial is to help determine: (1) safety and feasibility of ECCO-50 for osteoarthritis, (2) provide dosing guidance and (3) explore key trial endpoints useful for a phase III trial. As a proof of concept trial, ACT-OA was not sized or powered for statistical significance in any of the endpoints. The purpose of the interim 24 week partial unblinding in this trial is to provide early data that will facilitate key regulatory and business development discussions and provide better understanding of the therapeutic mechanism of action that may impact other clinical programs. The interim analysis pre-specifies the evaluation of a number of patient reported outcomes important in patients with osteoarthritis of the knee. A total of 94 patients were treated in the trial, 31 received a high dose of ECCO-50. Patients, providers and Cytori personnel remain blinded to individual patient treatment allocation and patient subgroup outcomes.
05:27 EDTADBEStocks with implied volatility movement; ADBE SBUX
Subscribe for More Information
February 5, 2016
12:26 EDTADBEOptions with increasing implied volatility
Subscribe for More Information
February 4, 2016
11:21 EDTPAYOptions with increasing call volume; FMC HST XME RIO BHP PAY DNDK BSX ALLY SWFT
11:06 EDTUTXUnited Technologies reaffirms FY16 adjusted EPS view of $6.30-$6.60
Subscribe for More Information
07:08 EDTUTXCowen to hold a forum
Subscribe for More Information
February 3, 2016
07:15 EDTCYTXCytori says Cytori Cell Therapy 'safe' and 'effective' in EU Phase 1 ED trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use